The IRP will bring life-saving medicines to UK patients from 1 January 2024
News
Study suggests cognitive decline could be linked to hippocampus shrinkage
The findings could benefit patients living with neurodegenerative conditions
NHS urges individuals to take up cervical screening invitations
Around 3,200 new cases of cervical cancer are diagnosed in the UK every year
Genentech and NVIDIA enter into strategic AI research collaboration
Both companies will use their platforms to accelerate drug discovery and development
Alladapt’s allergy treatment receives FDA fast track designation
ADP101 is an oral immunotherapy to treat multi-food and single-food allergies
PREDICTOM trial backed by €21m for early Alzheimer’s detection
The trial will use an AI screening platform to identify those most at risk of dementia
Thousands of men to participate in UK trial for prostate cancer
Prostate cancer is responsible for 12,000 deaths every year in the UK
Two charities co-fund £5.5m childhood cancer research programme
SMPaeds2 aims to advance precision medicines for children with relapsed cancer
Lab-grown blood vessels could potentially treat strokes and vascular dementia
Cerebral SVD contributes to 45% of dementia cases and 20% of ischaemic strokes
NHS expands COVID-19 research platform for other major diseases
The OpenSAFELY platform will support the discovery of new treatments
BHF and UKDRI announce first UK centre for vascular dementia research
The centre will help discover new treatments to prevent, halt and cure the condition
New NIHR Research Delivery Network in England announced by DHSC
The University of Leeds and NHS organisations will host the network in 2024
NHS trials artificial intelligence system to prevent avoidable admissions
The AI system will identify those most at risk and reduce pressure on the NHS
LifeArc and UKDRI invest £14.5m into neurodegeneration research
The funding will be used to develop new diagnostic tests, treatments and devices
Glox Therapeutics secures £4.3m seed funding to combat AMR
The bacteriocin development programme will first target pseudomonas aeruginosa
